IPN Virus Genome Mutations and Codon Interactions
AssigneeFVG Limited
InventorOystein Evensen
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to infectious pancreatic necrosis virus (IPNV) and specifically to further characterisation of the genetic stability of IPNV genome. More in particular, the invention relates to greater appreciation and understanding of the frequency of mutagenesis and codon interactions that influence the replication capabilities, virulence and immunogenicity of the virus. There is provided for the first time a method for developing a commercially applicable IPNV vaccine and a vaccine comprising the IPNV genome carrying particular mutations and codons. There are also described uses in prophylaxis or treatment of infectious pancreatic necrosis (IPN) disease.
Claims17
A live avirulent infectious pancreatic necrosis virus (IPNV) which does not revert to a virulent virus after at least 6 or at least 9 passages.
(canceled)
(canceled)
A method for identifying or producing an avirulent IPNV, the method comprising the steps of:
- a) characterising the distribution of nucleotides of VP2;
- b) correlating step a) with the distribution of nucleotides at codons starting at codon 200 to codon 320;
- and
- c) identifying or producing an avirulent IPNV.
(canceled)
(canceled)
The method according to claim 17, wherein the vaccine is administered to the subject by immersion, orally or by injection.
(canceled)
Dependencies are inferred from the claim text.